Skip to Main Content

Paper Details

Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study.
Eur Urol Oncol
34
2021
Author NameAffiliation
Tokhir DadaevThe Institute of Cancer Research
David E NealUniversity of Oxford, John Radcliffe Hospital, Addenbrooke's Hospital, University of Cambridge, Cambridge Research Institute
Graham G GilesThe University of Melbourne, School of Clinical Sciences at Monash Health, Monash University
Stephen N ThibodeauMayo Clinic
Shannon K McDonnellMayo Clinic
Chad D HuffThe University of Texas MD Anderson Cancer Center
Paul ScheetThe University of Texas MD Anderson Cancer Center
Paul ScheetThe University of Texas MD Anderson Cancer Center
Jennifer B PermuthMoffitt Cancer Center and Research Institute
Jennifer B PermuthMoffitt Cancer Center and Research Institute
Janet L StanfordFred Hutchinson Cancer Research Center, School of Public Health, University of Washington
Janet L StanfordFred Hutchinson Cancer Research Center, School of Public Health, University of Washington
James Y DaiFred Hutchinson Cancer Research Center
Elaine A OstranderNational Human Genome Research Institute
Elaine A OstranderNational Human Genome Research Institute
Johanna SchleutkerInstitute of Biomedicine, University of Turku, Turku University Hospital
Johanna SchleutkerInstitute of Biomedicine, University of Turku, Turku University Hospital
Fredrik WiklundKarolinska Institute
Henrik Gr??nbergKarolinska Institute
Henrik Gr??nbergKarolinska Institute
William B IsaacsJames Buchanan Brady Urological Institute, Johns Hopkins Hospital and Medical Institution
Melvin L K ChuaNational Cancer Centre Singapore, Singapore Duke-NUS Medical School
Daniel J SchaidMayo Clinic
Douglas F EastonThe Institute of Cancer Research, UK Royal Marsden NHS Foundation Trust
Zsofia Kote-JaraiThe Institute of Cancer Research
  • 1 - 25

Datasets